CG ONCOLOGY, INC.156944100US156944100906/04/2026To approve, on an advisory basis, the compensation of the Company's Named Executive Officers.SECTION 14A SAY-ON-PAY VOTESISSUER10040500FOR1004050FOR CG ONCOLOGY, INC.156944100US156944100906/04/2026To indicate, on an advisory basis, the preferred frequency of stockholder advisory votes on the compensation of the Company's Named Executive Officers.SECTION 14A SAY-ON-PAY VOTESISSUER100405001 YEAR1004050FOR DISC MEDICINE, INC.254604101US254604101106/18/2026To approve, on a non-binding, advisory basis, the compensation paid to the Company's named executive officers.SECTION 14A SAY-ON-PAY VOTESISSUER3740690FOR374069FOR HIMS & HERS HEALTH, INC.433000106US433000106006/11/2026Advisory approval of the Company's executive compensation.SECTION 14A SAY-ON-PAY VOTESISSUER7381510FOR738151FOR LYELL IMMUNOPHARMA, INC.55083R203US55083R203106/10/2026Approval, on a non-binding advisory basis, of the compensation of the company's named executive officers.SECTION 14A SAY-ON-PAY VOTESISSUER4770780FOR477078FOR NURIX THERAPEUTICS, INC.67080M103US67080M103605/15/2026To approve, on a non-binding advisory basis, the compensation of the Company's named executive officers as disclosed in the Proxy Statement.SECTION 14A SAY-ON-PAY VOTESISSUER2650000FOR265000FOR